Pratia Kraków’s impact at ASH 2025: driving hematology innovation

Pratia proudly highlights the strong scientific presence of its Kraków research site in Poland at the American Society of Hematology (ASH) Annual Meeting 2025. Results from multi-center Clinical Trials conducted at the site contribute to 24 scientific publications, co-authored by the site’s Principal Investigator, Prof. Wojciech Jurczak, included in this year’s ASH program.

This achievement reflects the Pratia Kraków Study Team’s deep expertise in hematology Clinical Trials and their continuous commitment to delivering innovative therapies to Patients through high-quality research.

A prestigious Late Breaking Abstract presentation

One study stands out in particular.

Professor Wojciech Jurczak, MD, PhD – Principal Investigator at Pratia Kraków – is among the first authors of the randomized phase III trial “Pirtobrutinib versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” For Sponsors and Investigators, this study’s findings  provide valuable insight into emerging targeted therapies for indolent B-cell lymphomas. Due to its scientific merit, the ASH Scientific Committee selected this work for a Late Breaking Abstract Session – one of the most distinguished presentation formats at the meeting and part of ASH’s official press program. Late Breaking abstracts are highlighted in ASH’s press materials to guide international media toward the year’s most influential advances in hematology. Prof. Jurczak will present the results on December  9^th  at 8:00am EST.

Professor Wojciech Jurczak, MD, PhD

ASH: the global stage for breakthroughs in hematology

The American Society of Hematology (ASH) Annual Meeting stands as one of the most influential scientific congresses in the global life-science community. Each year it brings together thousands of Physicians, Investigators, and Research Centers to present the newest breakthroughs in hematology, share data from pivotal Clinical Trials, and shape future therapeutic standards. The meeting is renowned for its rigorous scientific selection, and being featured at ASH is considered a significant achievement for any Investigator or Research Site.

Pratia Kraków contributes to 24 scientific findings presented at ASH 2025

This year brings another milestone for our organization. Pratia Kraków took part in multiple multi-center Clinical Trials whose results contribute to 24 scientific publications presented at ASH 2025. These include 22 abstracts and 2 presentations, reflecting years of coordinated efforts by the site’s Study Teams and Investigators.

One of these works, where Professor Jurczak is among the first authors, will be presented in the Late Breaking Session. The remaining scientific contributions represent the collective achievements of the Pratia Kraków team, whose consistent commitment to excellence continues to elevate our presence in global hematology research.

To find out more about Pratia Kraków, click here.

A shared success for our network

This year’s achievements embody the combined impact of our Research Sites across Europe. Over 23% of Pratia’s global experience lies in Oncology, and we support breakthrough research through exclusive oncology units in 4 countries and strong collaborations with embedded hospital-based sites throughout the continent. Our footprint across 8 countries gives Sponsors access to diverse Patient populations and operational consistency delivered through technology-enabled site management.

We thank Professor Jurczak and the entire Pratia Kraków team for representing our network on an international stage.

If you would like to connect with us regarding upcoming Clinical Trials, please contact our Feasibility department at feasibility@pratia.com